Sensus Healthcare, Inc. (SRTS) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Sensus Healthcare, Inc.'s filing signal turned negative.

Sensus Healthcare, Inc. is a medical device company specializing in non-invasive treatments for non-melanoma skin cancer (NMSC) and keloid scar prevention using its proprietary low-energy X-ray technology, Superficial Radiation Therapy (SRT). The company offers three SRT devices: SRT-100, SRT-100+, and SRT-100 Vision, with nearly one million patients treated globally to date. Sensus also provides operational healthcare offerings to dermatology clinics through its "Fair Deal Agreement" model, which involves a revenue-share arrangement for access to SRT technology and support services. The company's primary markets are private dermatology practices and radiation oncologists in the U.S., with a significant portion of sales historically concentrated in the U.S. and China.

Revenue is primarily driven by the sale of SRT devices and related services, including maintenance, repair, and operational support through its Fair Deal Agreement model. The company also generates revenue from leases of its superficial radiotherapy equipment.